SG11201809625RA - 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer - Google Patents
1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancerInfo
- Publication number
- SG11201809625RA SG11201809625RA SG11201809625RA SG11201809625RA SG11201809625RA SG 11201809625R A SG11201809625R A SG 11201809625RA SG 11201809625R A SG11201809625R A SG 11201809625RA SG 11201809625R A SG11201809625R A SG 11201809625RA SG 11201809625R A SG11201809625R A SG 11201809625RA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- company
- box
- indiana
- indianapolis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348457P | 2016-06-10 | 2016-06-10 | |
| PCT/US2017/035097 WO2017213919A1 (en) | 2016-06-10 | 2017-05-31 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809625RA true SG11201809625RA (en) | 2018-11-29 |
Family
ID=59031409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809625RA SG11201809625RA (en) | 2016-06-10 | 2017-05-31 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US9872853B2 (zh) |
| EP (1) | EP3468965B1 (zh) |
| JP (1) | JP6632746B2 (zh) |
| KR (1) | KR102241258B1 (zh) |
| CN (1) | CN109641881B (zh) |
| AR (1) | AR108586A1 (zh) |
| AU (1) | AU2017277833B2 (zh) |
| BR (1) | BR112018072872A2 (zh) |
| CA (1) | CA3027035C (zh) |
| CL (1) | CL2018003543A1 (zh) |
| CO (1) | CO2018013251A2 (zh) |
| CR (1) | CR20180579A (zh) |
| CY (1) | CY1123660T1 (zh) |
| DK (1) | DK3468965T3 (zh) |
| DO (1) | DOP2018000278A (zh) |
| EA (1) | EA037419B1 (zh) |
| EC (1) | ECSP19001734A (zh) |
| ES (1) | ES2797981T3 (zh) |
| HR (1) | HRP20200769T1 (zh) |
| HU (1) | HUE050155T2 (zh) |
| IL (1) | IL263497B (zh) |
| JO (1) | JOP20170131B1 (zh) |
| LT (1) | LT3468965T (zh) |
| MA (1) | MA45224B1 (zh) |
| MD (1) | MD3468965T2 (zh) |
| ME (1) | ME03744B (zh) |
| MX (1) | MX2018015275A (zh) |
| MY (1) | MY197462A (zh) |
| NZ (1) | NZ748500A (zh) |
| PE (1) | PE20190378A1 (zh) |
| PH (1) | PH12018502572A1 (zh) |
| PL (1) | PL3468965T3 (zh) |
| PT (1) | PT3468965T (zh) |
| RS (1) | RS60322B1 (zh) |
| SG (1) | SG11201809625RA (zh) |
| SI (1) | SI3468965T1 (zh) |
| TW (1) | TWI671294B (zh) |
| UA (1) | UA122526C2 (zh) |
| WO (1) | WO2017213919A1 (zh) |
| ZA (1) | ZA201807688B (zh) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| BR112018067964B1 (pt) | 2016-03-07 | 2024-01-16 | Enanta Pharmaceuticals, Inc | Composto, composição farmacêutica que o compreende e uso do referido composto |
| IL272941B2 (en) | 2017-08-28 | 2023-03-01 | Enanta Pharm Inc | Antiviral agents for viral hepatitis b |
| EP3703692A4 (en) * | 2017-11-01 | 2021-04-28 | Merck Sharp & Dohme Corp. | NEW SUBSTITUTED TETRAHYDROQUINOLINE COMPOUNDS USED AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS |
| US20210002371A1 (en) * | 2017-12-21 | 2021-01-07 | Brian A. Sherer | Combination of an anti-pd-l1 antibody and ido1 inhibitor for the treatment of cancer |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| EP3836928B1 (en) * | 2018-08-17 | 2024-02-14 | Merck Sharp & Dohme LLC | Novel substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors |
| BR112021005091A2 (pt) | 2018-09-21 | 2021-06-08 | Enanta Pharmaceuticals, Inc. | heterociclos funcionalizados como agentes antivirais |
| US12065438B2 (en) | 2018-11-06 | 2024-08-20 | Merck Sharp & Dohme Llc | Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors |
| CN113271946A (zh) | 2018-11-21 | 2021-08-17 | 英安塔制药有限公司 | 官能化杂环化合物作为抗病毒剂 |
| US11236111B2 (en) | 2019-06-03 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN114105961B (zh) * | 2021-12-10 | 2023-09-12 | 海南梵圣生物科技有限公司 | 一种ido1抑制剂(ly-3381916)制备方法 |
| CN114213310B (zh) * | 2021-12-31 | 2024-02-23 | 中国药科大学 | 吲哚啉化合物及其衍生物、制备方法、药物组合物和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4629657B2 (ja) * | 2003-04-11 | 2011-02-09 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物 |
| ME02461B (me) * | 2005-05-10 | 2017-02-20 | Incyte Holdings Corp | Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih |
| US7622495B2 (en) * | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| KR20100124272A (ko) * | 2008-02-07 | 2010-11-26 | 아보트 러보러터리즈 | 양성 알로스테릭 조절제로서의 아미드 유도체 및 이의 사용방법 |
| MY171866A (en) * | 2008-07-08 | 2019-11-05 | Incyte Holdings Corp | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| NO2694640T3 (zh) * | 2011-04-15 | 2018-03-17 | ||
| ES2733546T3 (es) * | 2013-03-15 | 2019-11-29 | Bristol Myers Squibb Co | Inhibidores de IDO |
| WO2015150097A1 (en) * | 2014-04-04 | 2015-10-08 | Iomet Pharma Ltd | Indole derivatives for use in medicine |
| UY36391A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| US11135221B2 (en) * | 2015-12-23 | 2021-10-05 | Moonshot Pharma Llc | Methods for inducing an immune response |
-
2017
- 2017-05-24 JO JOP/2017/0131A patent/JOP20170131B1/ar active
- 2017-05-24 AR ARP170101413A patent/AR108586A1/es unknown
- 2017-05-25 TW TW106117300A patent/TWI671294B/zh not_active IP Right Cessation
- 2017-05-31 PE PE2018003199A patent/PE20190378A1/es unknown
- 2017-05-31 SG SG11201809625RA patent/SG11201809625RA/en unknown
- 2017-05-31 PL PL17728990T patent/PL3468965T3/pl unknown
- 2017-05-31 JP JP2018563823A patent/JP6632746B2/ja not_active Expired - Fee Related
- 2017-05-31 DK DK17728990.7T patent/DK3468965T3/da active
- 2017-05-31 SI SI201730252T patent/SI3468965T1/sl unknown
- 2017-05-31 HU HUE17728990A patent/HUE050155T2/hu unknown
- 2017-05-31 ME MEP-2020-98A patent/ME03744B/me unknown
- 2017-05-31 CN CN201780035976.4A patent/CN109641881B/zh not_active Expired - Fee Related
- 2017-05-31 CR CR20180579A patent/CR20180579A/es unknown
- 2017-05-31 US US15/609,115 patent/US9872853B2/en active Active
- 2017-05-31 MY MYPI2018002369A patent/MY197462A/en unknown
- 2017-05-31 PT PT177289907T patent/PT3468965T/pt unknown
- 2017-05-31 LT LTEP17728990.7T patent/LT3468965T/lt unknown
- 2017-05-31 BR BR112018072872-1A patent/BR112018072872A2/pt not_active Application Discontinuation
- 2017-05-31 EA EA201892479A patent/EA037419B1/ru unknown
- 2017-05-31 US US16/307,612 patent/US10759786B2/en active Active
- 2017-05-31 CA CA3027035A patent/CA3027035C/en active Active
- 2017-05-31 MX MX2018015275A patent/MX2018015275A/es unknown
- 2017-05-31 AU AU2017277833A patent/AU2017277833B2/en not_active Ceased
- 2017-05-31 RS RS20200623A patent/RS60322B1/sr unknown
- 2017-05-31 NZ NZ748500A patent/NZ748500A/en not_active IP Right Cessation
- 2017-05-31 UA UAA201811735A patent/UA122526C2/uk unknown
- 2017-05-31 WO PCT/US2017/035097 patent/WO2017213919A1/en unknown
- 2017-05-31 MD MDE20190462T patent/MD3468965T2/ro unknown
- 2017-05-31 KR KR1020187035215A patent/KR102241258B1/ko active IP Right Grant
- 2017-05-31 EP EP17728990.7A patent/EP3468965B1/en active Active
- 2017-05-31 MA MA45224A patent/MA45224B1/fr unknown
- 2017-05-31 ES ES17728990T patent/ES2797981T3/es active Active
-
2018
- 2018-11-15 ZA ZA2018/07688A patent/ZA201807688B/en unknown
- 2018-12-04 IL IL263497A patent/IL263497B/en active IP Right Grant
- 2018-12-06 CO CONC2018/0013251A patent/CO2018013251A2/es unknown
- 2018-12-06 PH PH12018502572A patent/PH12018502572A1/en unknown
- 2018-12-10 CL CL2018003543A patent/CL2018003543A1/es unknown
- 2018-12-10 DO DO2018000278A patent/DOP2018000278A/es unknown
-
2019
- 2019-01-09 EC ECSENADI20191734A patent/ECSP19001734A/es unknown
-
2020
- 2020-05-12 HR HRP20200769TT patent/HRP20200769T1/hr unknown
- 2020-06-05 CY CY20201100508T patent/CY1123660T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201807949WA (en) | Engineered immunoglobulins with altered fcrn binding | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201803918VA (en) | Production of steviol glycosides in recombinant hosts | |
| SG11201809560QA (en) | Enhancer of zeste homolog 2 inhibitors | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |